Effects of prostaglandins on the bovine corpus luteum: granules, lipid inclusions and progesterone secretion.
Corpora lutea collected at 15, 30 and 60 min after prostaglandin F2 alpha (PGF2 alpha) treatment were compared to control corpora lutea at 60 min after saline treatment. There were decreases (P less than 0.05) in the relative percentages of cytoplasm occupied by granules in large luteal cells (LLC) by 30 min and in small luteal cells (SLC) by 60 min. Differences were not observed among the groups for lipid inclusions. Luteal progesterone was decreased at all post-PGF2 alpha treatment times when compared to 60-min controls (P less than 0.05). PGF2 alpha was then compared with prostaglandin F1 alpha (PGF1 alpha), prostaglandin E1 (PGE1), and 17-phenyl-18,19,20-trinor-prostaglandin F2 alpha (17-phenyl-PGF2 alpha) in 60-min trials with plasma progesterone and luteinizing hormone (LH) determined every 5 min. LH was not affected by these treatments. Like PGF2 alpha, 17-phenyl-PGF2 alpha induced a greater loss of granules from LLC then SLC. 17-phenyl-PGF2 alpha also induced an increase in the lipid content of LLC. Treatments with PGF2 alpha and 17-phenyl-PGF2 alpha were associated with decreased concentrations of luteal progesterone but PGF1 alpha and PGE1 were without effect on this variable. In contrast to PGF1 alpha, PGE1 increased both luteal progesterone and the area occupied by cytoplasmic granules. The latter effect was greater in LLC than SLC.(ABSTRACT TRUNCATED AT 250 WORDS)
D000527:Alprostadil; D000818:Animals; D002417:Cattle / Q000033:anatomy & histology*; D003338:Corpus Luteum / Q000187:drug effects* / Q000648:ultrastructure; D003594:Cytoplasmic Granules / Q000187:drug effects; D015237:Dinoprost / Q000031:analogs & derivatives; D005260:Female; D002479:Inclusion Bodies / Q000187:drug effects; D050356:Lipid Metabolism; D007986:Luteinizing Hormone / Q000097:blood; D008854:Microscopy, Electron; D011374:Progesterone / Q000097:blood / Q000378:metabolism*; D011453:Prostaglandins / Q000494:pharmacology*; D011458:Prostaglandins E / Q000494:pharmacology; D011460:Prostaglandins F / Q000494:pharmacology; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology
D011453:Prostaglandins; D011458:Prostaglandins E; D011460:Prostaglandins F; D011461:Prostaglandins F, Synthetic; D011374:Progesterone; C027042:17-phenylprostaglandin F2alpha; D007986:Luteinizing Hormone; D015237:Dinoprost; D000527:Alprostadil; C100006:prostaglandin F1